Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Assessment of 2012 Bioequivalence Standards for Warfarin

1. august 2019 opdateret af: University of California, San Francisco

Assessment of 2012 Bioequivalence Standards for Narrow Therapeutic Index Drugs: a Study With Warfarin

The purpose of this study is to assess the 2012 bioequivalence statistical criteria for warfarin, a narrow therapeutic index drug, set forth in the draft guidance issued by the Food and Drug Administration (FDA).

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study is a reasonable starting point to assess the appropriateness of the 2012 FDA bioequivalence (BE) statistical criteria for narrow therapeutic index drugs (NTIDs). The idea stems from an earlier study conducted in Dr. Benet's lab with the drug furosemide. The furosemide study yielded triplicate data that were unable to purely meet the BE statistical criteria set forth by the FDA due to the inherent study design. Furosemide is not an NTID to be considered by the FDA for BE studies, however. Hence, the investigators have proposed a new study to assess the BE statistical criteria with warfarin, an NTID with a draft guidance issued by the FDA. By providing the reference product (brand name warfarin) three times to each study participant and recording the relevant pharmacokinetic parameters for BE (AUC and Cmax), the investigators can make three comparisons between the data (R1 and R2 vs. R2 and R3; R1 and R2 vs. R1 and R¬3; R2 and R3 vs. R1 and R3).

The investigators have three concerns that can be tested here.

  1. Will normal within subject variability potentially lead to inequivalence of the reference product using the new NTID BE regulations?
  2. Is it possible that the BE interval could be less than the United States Pharmacopeia (USP) content uniformity limits for warfarin?
  3. Provide a comparison of the within-subject variance for the 2.5 ratio comparison.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

10

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • California
      • San Francisco, California, Forenede Stater, 94143
        • University of California, San Francisco

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 60 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female aged 18-60 years
  • Healthy adult without active medical problems or chronic diseases based on medical history, physical exam, and laboratory results
  • BMI 18.5-32 kg/m2
  • Ceased all medications 2 weeks prior to start of study and during study enrollment (includes drugs of abuse, prescription medications, and over-the-counter (OTC) medications [exception: acetaminophen])
  • Maintain adequate birth control independent of hormonal contraceptive use throughout study
  • Provide written informed consent to take part in and comply with the requirements of the study
  • Speak, read, and understand English
  • Avoid alcohol, caffeine, and orange juice from 6pm the night before the study day until the completion of the study day
  • Avoid contact sports and/or other activities with significant risk of trauma injury for 7 days after each study day
  • Do not eat food or consume beverages at least 8 hours before medication dosing
  • Present with wild type VKORC1, VKORC-1639G>A and wild type CYP2C9 genotype

Exclusion Criteria:

  • Subjects on prescription or chronic OTC medications (including hormonal contraceptives)
  • Subjects with known allergy to warfarin
  • Subjects with a history of or diagnosis of hemorrhagic tendencies or blood dyscrasias
  • Subjects with liver failure or liver function tests (LFTs) > 2x upper limit normal
  • Subjects with clinically significant elevations of international normalized ratio (INR), prothrombin time (PT), partial thromboplastin time (PTT), serum creatinine (Scr), blood urea nitrogen (BUN), or other screening laboratory tests as determined by study physician
  • Subjects with hematocrit (Hct) < 30 mg/dL
  • Subjects with history of GI bleed or peptic ulcer disease
  • Subjects with recent history of trauma
  • Subjects with recent history of or upcoming plan for surgery
  • Subjects who smoke tobacco
  • Subjects with ongoing alcohol use
  • Subjects with ongoing illegal drug use
  • Subjects who are pregnant, attempting to become pregnant, or lactating
  • Subjects who are unable to maintain adequate birth control during the study
  • Subjects who are unable to follow protocol instructions or criteria
  • Subjects with genotypes that are not wild type VKORC1, VKORC-1639G>A and wild type CYP2C9

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: warfarin
Subjects will receive a single dose of warfarin 10 mg PO at each of 3 visits. The study days will be separated by at least 14 days to allow adequate time for the drug to reach washout.
Medicin: warfarin
warfarin 10 mg PO x 1
Andre navne:
  • Coumadin
  • Jantoven

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
S- and R- enantiomers of warfarin (S-warfarin, R-warfarin) Area Under the Plasma Concentration-Time Curve (AUC) from 0 to 72 hours
Tidsramme: 0 to 72 hours after warfarin dosing
The primary outcome measure will be warfarin area-under-the-concentration-time curve (AUC) values from zero to seventy-two (0-72) hours. Values from the Experimental Arm (warfarin) of each the 3 study periods will be compared against each other and analyzed for intra-individual variability and tested for bioequivalence using the new narrow therapeutic index drug (NTID) regulations. Blood collection at 0, 1, 2, 3, 4, 6, 8, 12 hours after warfarin dosing.
0 to 72 hours after warfarin dosing

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
S- and R- enantiomers of warfarin (S-warfarin, R-warfarin) Area Under the Plasma Concentration-time Curve (AUC) from time zero to infinity hours
Tidsramme: 0 to 8 weeks after warfarin dosing
A secondary outcome measure will be warfarin area-under-the-concentration-time curve (AUC) values from zero to infinite time (0-inf) where infinite time represents the duration of the study (8 weeks). Values from the Experimental Arm (warfarin) of each the 3 study periods will be compared against each other and analyzed for intra-individual variability and tested for bioequivalence using the new narrow therapeutic index drug (NTID) regulations. Analysis of all concentration-time data; blood collection at 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours after warfarin dosing.
0 to 8 weeks after warfarin dosing
Maximum Plasma Concentration (Cmax) of S-warfarin and R-warfarin
Tidsramme: 0 to 72 hours after warfarin dosing
A secondary outcome measure will be maximum plasma concentration (Cmax). Values from the Experimental Arm (warfarin) of each the 3 study periods will be compared against each other and analyzed for intra-individual variability and tested for bioequivalence using the new narrow therapeutic index drug (NTID) regulations. Blood collection 0, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours after warfarin dosing.
0 to 72 hours after warfarin dosing

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

University of California, San Francisco

Efterforskere

  • Ledende efterforsker: Leslie Z Benet, PhD, University of California, San Francisco
  • Ledende efterforsker: Lynda A Frassetto, MD, University of California, San Francisco

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. maj 2016

Primær færdiggørelse (Faktiske)

1. februar 2019

Studieafslutning (Faktiske)

1. februar 2019

Datoer for studieregistrering

Først indsendt

9. september 2015

Først indsendt, der opfyldte QC-kriterier

9. oktober 2015

Først opslået (Skøn)

14. oktober 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. august 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. august 2019

Sidst verificeret

1. august 2019

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 15-17226

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med warfarin

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in India

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner